摘要
细胞内钙离子浓度的增加在许多癌症特征的建立起着关键作用,包括异常增殖、迁移、入侵、抗凋亡和抗血管再生。钙离子进入失调是一种最微妙的机制,通过这种机制癌细胞消灭同行并且获得自适应优势,从而在整个有机体实现肿瘤生长,血管生成和传播。组成型和激动剂诱导的钙内流可能被贮存依赖以及贮存独立钙离子进入路线介导。越来越多的证据表明,癌症细胞里不同亚型的基质互动分子(Stim)和Orai蛋白质,即Stim1,Stim2,Orai1和Orai3以这两种途径为基础。无论是Stim和Orai蛋白的表达还是活动都已被链接到在许多实体瘤肿瘤表型的发生和维持上 ,包括前列腺癌、乳腺癌、肾,食管,皮肤,大脑,大肠癌,肺和肝等器官癌症。这里,我们调查现有数据以支持Stim和Orai在肿瘤发生关系的参与度并针对癌症患者提供基本原理。此外,我们总结了新的药理学鉴定工具方面的进步,这些工具已成功用于临床医疗。
关键词: Stim
Current Medicinal Chemistry
Title:Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy
Volume: 23 Issue: 30
Author(s): Francesco Moccia, Estella Zuccolo, Valentina Poletto, Ilaria Turin, Germano Guerra, Paolo Pedrazzoli, Vittorio Rosti and Camillo Porta, Daniela Montagna
Affiliation:
关键词: Stim
摘要: An increase in intracellular Ca2+ concentration plays a key role in the establishment of many cancer hallmarks, including aberrant proliferation, migration, invasion, resistance to apoptosis and angiogenesis. The dysregulation of Ca2+ entry is one of the most subtle mechanisms by which cancer cells overwhelm their normal counterparts and gain the adaptive advantages that result in tumour growth, vascularisation and dissemination throughout the organism. Both constitutive and agonist-induced Ca2+ influx may be mediated by store-dependent as well as store-independent Ca2+ entry routes. A growing body of evidences have shown that different isoforms of Stromal Interaction Molecules (Stim1) and Orai proteins, i.e. Stim1, Stim2, Orai1 and Orai3, underlie both pathways in cancer cells. The alteration in either the expression or the activity of Stim and Orai proteins has been linked to the onset and maintenance of tumour phenotype in many solid malignancies, including prostate, breast, kidney, esophageal, skin, brain, colorectal, lung and liver cancers. Herein, we survey the existing data in support of Stim and Orai involvement in tumourigenesis and provide the rationale to target them in cancer patients. Besides, we summarize the most recent advances in the identification of novel pharmacological tools that could be successfully used in clinical therapy.
Export Options
About this article
Cite this article as:
Francesco Moccia, Estella Zuccolo, Valentina Poletto, Ilaria Turin, Germano Guerra, Paolo Pedrazzoli, Vittorio Rosti and Camillo Porta, Daniela Montagna , Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy, Current Medicinal Chemistry 2016; 23 (30) . https://dx.doi.org/10.2174/0929867323666160607111220
DOI https://dx.doi.org/10.2174/0929867323666160607111220 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia
Current Cancer Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cellomics as Integrative Omics for Cancer
Current Proteomics Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Novel Concepts in the Development of Platinum Antitumour Drugs: An Update
Medicinal Chemistry Reviews - Online (Discontinued) The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets A Review on Synthesis, Anticancer and Antiviral Potentials of Pyrimidine Derivatives
Current Bioactive Compounds Therapeutic Outlook of Pyrazole Analogs: A Mini Review
Mini-Reviews in Medicinal Chemistry Progress Towards Recombinant Anti-Infective Antibodies
Recent Patents on Anti-Infective Drug Discovery Bone Metastasis-Related MicroRNAs: New Targets for Treatment?
Current Cancer Drug Targets KRAB-Zinc Finger Proteins: A Repressor Family Displaying Multiple Biological Functions
Current Genomics Antiproliferative Activity of 8-methoxy Ciprofloxacin-Hydrozone/Acylhydrazone Scaffolds
Current Topics in Medicinal Chemistry Evaluation of the in vitro Chemosensitivity and Correlation with Clinical Outcomes in Lung Cancer using the ATP-TCA
Anti-Cancer Agents in Medicinal Chemistry Synthesis of Nitroaromatic Compounds as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection
Infectious Disorders - Drug Targets The Genetic Landscapes of Inflammation-Driven Gastrointestinal Tract Cancers
Current Pharmaceutical Design Plant Secondary Metabolites in Cancer Chemotherapy: Where are We?
Current Pharmaceutical Biotechnology Regulation of the Urokinase Receptor (uPAR) by LDL Receptor-related Protein-1 (LRP1)
Current Pharmaceutical Design Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics